Answers are grounded in this paper and cite their sources.
Clinical investigation demonstrates the safety and efficacy of denosumab in fibrous dysplasia of bone, highlighting its therapeutic potential against GNAS-driven skeletal lesions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: